Waterfront Wealth Inc. increased its position in shares of Amarin Co. plc (NASDAQ:AMRN - Free Report) by 181.4% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 2,481,766 shares of the biopharmaceutical company's stock after acquiring an additional 1,599,956 shares during the quarter. Waterfront Wealth Inc. owned approximately 0.60% of Amarin worth $1,204,000 as of its most recent filing with the SEC.
A number of other hedge funds have also recently bought and sold shares of AMRN. Arkfeld Wealth Strategies L.L.C. boosted its position in Amarin by 52.6% during the fourth quarter. Arkfeld Wealth Strategies L.L.C. now owns 58,000 shares of the biopharmaceutical company's stock worth $30,000 after acquiring an additional 20,000 shares during the last quarter. China Universal Asset Management Co. Ltd. boosted its position in Amarin by 63.9% during the third quarter. China Universal Asset Management Co. Ltd. now owns 76,959 shares of the biopharmaceutical company's stock worth $48,000 after acquiring an additional 29,992 shares during the last quarter. Kornitzer Capital Management Inc. KS boosted its position in Amarin by 80.7% during the third quarter. Kornitzer Capital Management Inc. KS now owns 95,600 shares of the biopharmaceutical company's stock worth $60,000 after acquiring an additional 42,700 shares during the last quarter. New York State Common Retirement Fund acquired a new stake in Amarin during the fourth quarter worth approximately $68,000. Finally, LCM Capital Management Inc boosted its position in Amarin by 3.1% during the fourth quarter. LCM Capital Management Inc now owns 838,259 shares of the biopharmaceutical company's stock worth $407,000 after acquiring an additional 25,100 shares during the last quarter. Institutional investors and hedge funds own 22.25% of the company's stock.
Amarin Stock Down 0.0 %
NASDAQ:AMRN opened at $0.59 on Friday. The company has a market cap of $242.71 million, a P/E ratio of -6.57 and a beta of 1.83. Amarin Co. plc has a fifty-two week low of $0.43 and a fifty-two week high of $1.36. The firm's 50 day moving average is $0.54 and its two-hundred day moving average is $0.56.
Analyst Upgrades and Downgrades
Separately, StockNews.com raised shares of Amarin from a "sell" rating to a "hold" rating in a research note on Tuesday, February 11th.
Check Out Our Latest Analysis on Amarin
Amarin Profile
(
Free Report)
Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Amarin, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amarin wasn't on the list.
While Amarin currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
